Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

Novo Nordisk (NYSE: NVO) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish ...

Novo Nordisk shares surged after Eli Lilly's weight-loss pill underperformed expectations in trial results. This setback is ...

Generalists, on the other hand, view Novo as leading in sales force image and being on par with Lilly in other key aspects of image. Merck followed as a close third among PCPs in all aspects of image.